1.Mechanical Thrombectomy for Acute Middle Cerebral Artery Occlusion Caused by a Giant, Thrombosed, Extracranial Internal Carotid Artery Aneurysm.
Odysseas KARGIOTIS ; Georgios MAGOUFIS ; Apostolos SAFOURIS ; Aristeidis H KATSANOS ; Eleftherios STAMBOULIS ; Georgios TSIVGOULIS
Journal of Clinical Neurology 2017;13(2):196-198
No abstract available.
Aneurysm*
;
Carotid Artery, Internal*
;
Infarction, Middle Cerebral Artery*
;
Middle Cerebral Artery*
;
Thrombectomy*
2.Erratum: Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke.
Georgios TSIVGOULIS ; Apostolos SAFOURIS ; Dong Eog KIM ; Andrei V ALEXANDROV
Journal of Stroke 2018;20(3):417-417
On page 149, 9th line of the third paragraph in ‘Antiplatelet therapy,’‘without’ was misspelled. The correct word is ‘with.’
3.Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke.
Georgios TSIVGOULIS ; Apostolos SAFOURIS ; Dong Eog KIM ; Andrei V ALEXANDROV
Journal of Stroke 2018;20(2):145-166
Atherosclerosis is a major cause of ischemic stroke that can be effectively prevented with appropriate lifestyle modifications and control of cardiovascular risk factors. Medical advances in recent years along with aggressive cardiovascular risk factor modifications have resulted in decreased recurrence rates of atherosclerotic stroke. Non-statin lipid-lowering molecules have recently shown clinical benefit and are recommended for very high-risk patients to reduce their risk of stroke. Aggressive hypertension treatment is crucial to reduce atherosclerotic stroke risk. Advances in antithrombotic treatments include combinations of antiplatelets and new antiplatelet agents in the acute phase post-stroke, which carries a high risk of recurrence. Intensive medical treatment has also limited the indications for carotid interventions, especially for asymptomatic disease. Intracranial atherosclerotic disease may provoke stroke through various mechanisms; it is increasingly recognized as a cause of ischemic stroke with advanced imaging and is best managed with lifestyle modifications and medical therapy. The diagnostic search for the vulnerable culprit atherosclerotic plaque is an area of intense research, from the level of the intracranial arteries to that of the aortic arch. Ultrasonography and novel magnetic resonance imaging techniques (high-resolution vessel-wall imaging) may assist in the identification of vulnerable atherosclerotic plaques as the underlying cause in cryptogenic or misdiagnosed non-atherosclerotic ischemic stroke. Vertebrobasilar atherosclerotic disease is less common than carotid artery disease; thus, high-quality data on effective prevention strategies are scarcer. However, aggressive medical treatment is also the gold standard to reduce cerebrovascular disease located in posterior circulation.
Aorta, Thoracic
;
Arteries
;
Asymptomatic Diseases
;
Atherosclerosis
;
Carotid Artery Diseases
;
Cerebrovascular Disorders
;
Dyslipidemias
;
Humans
;
Hypertension
;
Life Style
;
Magnetic Resonance Imaging
;
Plaque, Atherosclerotic
;
Platelet Aggregation Inhibitors
;
Recurrence
;
Risk Factors
;
Secondary Prevention*
;
Stroke*
;
Ultrasonography
4.Ultra-Early Remote Intracranial Hemorrhage Complicating Intravenous Thrombolysis with Tenecteplase for Acute Ischemic Stroke
Odysseas KARGIOTIS ; Apostolos SAFOURIS ; Klearchos PSYCHOGIOS ; Maria CHONDROGIANNI ; Athina ANDRIKOPOULOU ; Aikaterini THEODOROU ; Georgios MAGOUFIS ; Eleftherios STAMBOULIS ; Georgios TSIVGOULIS
Journal of Clinical Neurology 2020;16(4):696-698
5.Timing of Recanalization and Functional Recovery in Acute Ischemic Stroke
Georgios TSIVGOULIS ; Maher SAQQUR ; Vijay K. SHARMA ; Alejandro BRUNSER ; Jürgen EGGERS ; Robert MIKULIK ; Aristeidis H. KATSANOS ; Theodore N. SERGENTANIS ; Konstantinos VADIKOLIAS ; Fabienne PERREN ; Marta RUBIERA ; Reza BAVARSAD SHAHRIPOUR ; Huy Thang NGUYEN ; Patricia MARTÍNEZ-SÁNCHEZ ; Apostolos SAFOURIS ; Ioannis HELIOPOULOS ; Ashfaq SHUAIB ; Carol DERKSEN ; Konstantinos VOUMVOURAKIS ; Theodora PSALTOPOULOU ; Anne W. ALEXANDROV ; Andrei V. ALEXANDROV ;
Journal of Stroke 2020;22(1):130-140
Background:
and Purpose Although onset-to-treatment time is associated with early clinical recovery in acute ischemic stroke (AIS) patients treated with intravenous tissue plasminogen activator (tPA), the effect of the timing of tPA-induced recanalization on functional outcomes remains debatable.
Methods:
We conducted a multicenter, prospective observational cohort study to determine whether early (within 1-hour from tPA-bolus) complete or partial recanalization assessed during 2-hour real-time transcranial Doppler monitoring is associated with improved outcomes in patients with proximal occlusions. Outcome events included dramatic clinical recovery (DCR) within 2 and 24-hours from tPA-bolus, 3-month mortality, favorable functional outcome (FFO) and functional independence (FI) defined as modified Rankin Scale (mRS) scores of 0–1 and 0–2 respectively.
Results:
We enrolled 480 AIS patients (mean age 66±15 years, 60% men, baseline National Institutes of Health Stroke Scale score 15). Patients with early recanalization (53%) had significantly (P<0.001) higher rates of DCR at 2-hour (54% vs. 10%) and 24-hour (63% vs. 22%), 3-month FFO (67% vs. 28%) and FI (81% vs. 39%). Three-month mortality rates (6% vs. 17%) and distribution of 3-month mRS scores were significantly lower in the early recanalization group. After adjusting for potential confounders, early recanalization was independently associated with higher odds of 3-month FFO (odds ratio [OR], 6.19; 95% confidence interval [CI], 3.88 to 9.88) and lower likelihood of 3-month mortality (OR, 0.34; 95% CI, 0.17 to 0.67). Onset to treatment time correlated to the elapsed time between tPA-bolus and recanalization (unstandardized linear regression coefficient, 0.13; 95% CI, 0.06 to 0.19).
Conclusions
Earlier tPA treatment after stroke onset is associated with faster tPA-induced recanalization. Earlier onset-to-recanalization time results in improved functional recovery and survival in AIS patients with proximal intracranial occlusions.
6.Update of Anticoagulation Use in Cardioembolic Stroke With a Special Reference to Endovascular Treatment
Apostolos SAFOURIS ; Klearchos PSYCHOGIOS ; Lina PALAIODIMOU ; Peter OROSZ ; George MAGOUFIS ; Odysseas KARGIOTIS ; Aikaterini THEODOROU ; Theodore KARAPANAYIOTIDES ; Stavros SPILIOPOULOS ; Sándor NARDAI ; Amrou SARRAJ ; Thanh N. NGUYEN ; Shadi YAGHI ; Silke WALTER ; Simona SACCO ; Guillaume TURC ; Georgios TSIVGOULIS
Journal of Stroke 2024;26(1):13-25
Cardioembolic stroke is a major cause of morbidity, with a high risk of recurrence, and anticoagulation represents the mainstay of secondary stroke prevention in most patients. The implementation of endovascular treatment in routine clinical practice complicates the decision to initiate anticoagulation, especially in patients with early hemorrhagic transformation who are considered at higher risk of hematoma expansion. Late hemorrhagic transformation in the days and weeks following stroke remains a potentially serious complication for which we still do not have any established clinical or radiological prediction tools. The optimal time to initiate therapy is challenging to define since delaying effective secondary prevention treatment exposes patients to the risk of recurrent embolism. Consequently, there is clinical equipoise to define and individualize the optimal timepoint to initiate anticoagulation combining the lowest risk of hemorrhagic transformation and ischemic recurrence in cardioembolic stroke patients. In this narrative review, we will highlight and critically outline recent observational and randomized relevant evidence in different subtypes of cardioembolic stroke with a special focus on anticoagulation initiation following endovascular treatment. We will refer mainly to the commonest cause of cardioembolism, non-valvular atrial fibrillation, and examine the possible risk and benefit of anticoagulation before, during, and shortly after the acute phase of stroke. Other indications of anticoagulation after ischemic stroke will be briefly discussed. We provide a synthesis of available data to help clinicians individualize the timing of initiation of oral anticoagulation based on the presence and extent of hemorrhagic transformation as well as stroke severity.